Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Garetosmab and Trevogrumab in Sporadic Inclusion Body Myositis
NCT03710941Phase 2Withdrawn
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2019
- Primary completion
- Aug 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of garetosmab, trevogrumab in sporadic inclusion body myositis (sIBM), sponsored by Regeneron Pharmaceuticals. Planned start Feb 2019; status: withdrawn.
02
Drugs
garetosmabtrevogrumab
03
Conditions
sporadic inclusion body myositis (sIBM)
Beyond the preview
Go deeper on NCT03710941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03710941.